KB 9558
Alternative Names: KB-9558Latest Information Update: 14 Jun 2024
At a glance
- Originator Kronos Bio
- Class Antineoplastics; Small molecules
- Mechanism of Action P300-CBP transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Multiple myeloma
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Multiple myeloma released by Kronos Bio
- 07 Mar 2024 Kronos Bio plans a first-in-human phase I trial in Multiple myeloma (Second-line therapy or greater) in the first half of 2025
- 18 Dec 2023 Preclinical trials in Multiple myeloma in USA (unspecified route) prior to December 2023